

## Genotype-Phenotype Correlation - Two Families with *GCH1* Mutations

Ya-Ping Yan<sup>1</sup> and Bo Zhang<sup>2\*</sup>

<sup>1</sup>Department of Neurology, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, PR China

<sup>2</sup>Department of Surgery, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, PR China

### Abstract

Dopa-responsive dystonia (DRD), attributed to GTP cyclohydrolase 1 (*GCH1*) mostly, is a clinically and genetically heterogeneous disorder. Our recent study have identified that phenotype may not be identical to genotype, even in the same family. One patient with parkinsonism was found to carry *GCH1* mutation. Why phenotype is not correlated to genotype? Whether *GCH1* is a risk factor for developing Parkinson's disease (PD)? Further genetic and clinical studies are necessary to elucidate these questions.

**Keywords:** Dopa-responsive dystonia (DRD); *GCH1* gene; *TH* gene; Parkinson's disease (PD)

### Introduction

Dopa-responsive dystonia (DRD) was first discovered by Segawa et al. in 1972 [1]. It is a progressive primary dystonia characterized by onset during childhood, marked diurnal fluctuation and a dramatic and long-term response to low doses of levodopa [2]. Mostly, defects in the GTP cyclohydrolase 1 (*GCH1*) gene and the tyrosine hydroxylase (*TH*) gene have been attributed to the pathogenesis of DRD [3]. The characteristics of low CSF homovanillic acid (HVA) levels with low HVA/5-hydroxyindolacetic acid (5-HIAA) ratio were discovered in DRD patients [4]. In our previous study, we found that the clinical phenotypes of patients in one pedigree may be different with the same mutation in one family.

### Clinical Phenotype of a Family with *GCH1*(c.550C>T) Mutation

A reported heterozygous mutation of *GCH1* (c.550C>T) was detected in a family [5]. The age of onset of affected patients ranged from 13 to 60 years. Treatment with levodopa results in clinical improvement. However, the dose of levodopa varied from 50 mg twice daily to 100 mg twice daily. The mother of the affected patients was still normal at age 80, who carried the same mutation. The same feature had been reported in previous paper [6-8].

### Clinical Phenotype of a Family with *GCH1*(c. IVS2-2A>G) Mutation

In another family, the father/daughter pair carrying the IVS2-2A>G *GCH1* mutation showed different phenotypes [9]. The daughter was diagnosed at age 8 with the symptom of dystonia. She presented excellent response to dopaminergic medications. However, her father was normal before the age of 53, Clinical examination showed asymmetrical bradykinesia, hypomimia, slow gait and poor postural reflexes, actually, more like parkinsonism. He preferred taking L-dopa (100 mg, twice daily), amantadine (100 mg, twice daily) and selegiline (5 mg, daily) to completely control symptoms. The patient was the only one who carried parkinsonian symptoms in our study of DRD patients, which supported the point of view that some *GCH1* coding variants or mutation, like Q110X, V204I, might be associated with Parkinson's disease (PD) [10].

### Some Issues need Further Thinking

Here, we show that the clinical phenotypes of DRD patients might

be nonspecific. Old age and the symptom of parkinsonism should not be excluded, even with a negative family history. There are a number of issues worth considering. First, why the symptom varied for patients with the same mutation? It might be that apart from the exons, non-coding regions, promotor system, microRNA and other factors may all contributed to this disease [11-13]. Second, is *GCH1* related to PD? Previous studies from Taiwan revealed parkinsonian features were common to DRD in 1996. Later, Shang et al. reported 5 of 16 DRD patients developed parkinsonism symptoms. However, in 2014, it was shown that the frequency of *GCH1* variants was significantly higher in PD cases than in controls by Mencacci et al. (1% and 0.75%, p=0.0001). The authors also presented 4 patients with different *GCH1* mutations fully met the Criteria for definite PD [10]. In 2015, Wang et al. reported a family with a novel *GCH1* variant displayed different phenotypes of PD and DRD. In addition, it was also demonstrated that *GCH1* rs11158026 increased the risk of developing PD [14]. Whether parkinsonism is an atypical symptom of DRD or *GCH1* is a gene responsible for PD?

### Conclusion

In further studies, we should do more research on non-coding regions of *GCH1* gene to explain some phenotype variation, thus provide some strategies for new treatment. More *GCH1* screening should be done in subjects with parkinsonism. And apart from gene test, cerebrospinal fluid (CSF) detection and Dopamine transporter imaging are also recommended to help differentiate between PD and DRD [10,15].

### Acknowledgement

The authors acknowledge the patients and their families for their important help in data acquisition and the Cancer Institute of Zhejiang University for technical assistance and advice. This work was supported by grants from the National Natural Science Foundation of China (No. 81570698) and (No.81200984), the Natural Science Foundation of Zhejiang Province (LY16H070003).

\*Corresponding author: Dr. Bo Zhang, Department of Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88 Jiefang Road, Hangzhou, Zhejiang 310009, PR China, Tel: +8657187783563; E-mail: [doctormd@126.com](mailto:doctormd@126.com)

Received May 16, 2017; Accepted May 22, 2017; Published May 29, 2017

Citation: Yan YP, Zhang B (2017) Genotype-Phenotype Correlation - Two Families with *GCH1* Mutations. Adv Tech Biol Med 5: 225. doi: [10.4172/2379-1764.1000225](https://doi.org/10.4172/2379-1764.1000225)

Copyright: © 2017 Yan YP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## References

1. Segawa M, Ohmi K, Itoh S, Aoyama M, Hayakawa H (1972) Childhood basal ganglia disease with marked response to L-Dopa: Hereditary progressive basal ganglia disease with marked diurnal fluctuation. *Shinryo* 24: 667-672.
2. Segawa M, Hosaka A, Miyagawa F, Nomura Y, Imai H (1976) Hereditary progressive dystonia with marked diurnal fluctuation. *Adv Neurol* 14: 215-233.
3. Lee WW, Jeon BS (2014) Clinical spectrum of dopa-responsive dystonia and related disorders. *Curr Neurol Neurosci Rep* 14: 461.
4. Mak CM, Lam CW, Siu TS, Chan KY, Siu WK, et al. (2010) Biochemical and molecular characterization of tyrosine hydroxylase deficiency in Hong Kong Chinese. *Mol Genet Metab* 99: 431-433.
5. Yan YP, Chen XH, Luo W (2017) Analysis of clinical phenotype and GCH1 gene mutations in a family affected with dopa-responsive dystonia. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 34: 205-208.
6. Cai C, Shi W, Zeng Z, Zhang M, Ling C, et al. (2013) GTP cyclohydrolase I and tyrosine hydroxylase gene mutations in familial and sporadic dopa-responsive dystonia patients. *PLoS ONE* 8: e65215.
7. Furukawa Y, Lang AE, Trugman JM, Bird TD, Hunter A, et al. (1998) Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. *Neurology* 50: 1015-1020.
8. Takahashi H, Levine RA, Galloway MP, Snow BJ, Calne DB, et al. (1994) Biochemical and fluorodopa positron emission tomographic findings in an asymptomatic carrier of the gene for dopa-responsive dystonia. *Ann Neurol* 35: 354-356.
9. Yan YP, Zhang B, Mao YF, Guo ZY, Tian J, et al. (2017) A novel tyrosine hydroxylase variant in a group of Chinese patients with dopa-responsive dystonia. *Int J Neurosci* 127: 694-700.
10. Mencacci NE, Isaias IU, Reich MM, Ganos C, Plagnol V, et al. (2014) Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. *Brain* 137: 2480-2492.
11. Theuns J, Crosiers D, Debaene L, Nuytemans K, Meeus B, et al. (2012) Guanosine triphosphate cyclohydrolase 1 promoter deletion causes dopa-responsive dystonia. *Mov Disord* 27: 1451-1456.
12. Skrygan M, Bartholomé B, Bonafé L, Blau N, Bartholomé K (2001) A splice mutation in the GTP cyclohydrolase I gene causes dopa-responsive dystonia by exon skipping. *J Inher Metab Dis* 24: 345-351.
13. Souza CP, Valadares ER, Trindade AL, Rocha VL, Oliveira LR, et al. (2008) Mutation in intron 5 of GTP cyclohydrolase 1 gene causes dopa-responsive dystonia (Segawa syndrome) in a Brazilian family. *Genet Mol Res* 7: 687-694.
14. Wang L, Cheng L, Li NN, Yu WJ, Sun XY, et al. (2016) Association of four new candidate genetic variants with Parkinson's disease in a Han Chinese population. *Am J Med Genet B Neuropsychiatr Genet* 171B: 342-347.
15. Lee WW, Jeon BS (2014) Clinical spectrum of dopa-responsive dystonia and related disorders. *Current neurology and neuroscience reports* 14: 461.

Citation: Yan YP, Zhang B (2017) Genotype-Phenotype Correlation - Two Families with GCH1 Mutations. Adv Tech Biol Med 5: 225. doi: [10.4172/2379-1764.1000225](https://doi.org/10.4172/2379-1764.1000225)

## OMICS International: Open Access Publication Benefits & Features

### Unique features:

- Increased global visibility of articles through worldwide distribution and indexing
- Showcasing recent research output in a timely and updated manner
- Special issues on the current trends of scientific research

### Special features:

- 700+ Open Access Journals
- 50,000+ editorial team
- Rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at major indexing services
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: <http://www.omicsonline.org/submit/>